All In Biotech

Drug Trial Radar · NCT01813435

GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-platelet Therapy After Stent Implantation

Last checked: Nov 20, 2026Latest source record: Mar 15, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 15,991 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

15,991

Actual

Start

Jul 1, 2013

Primary completion

Nov 9, 2015

Study completion Apr 26, 2018

Sponsor

Lead sponsor
ECRI bvIndustry
Sponsor type
Industry
Collaborators
Biosensors International; AstraZeneca; The Medicines Company
First posted
Mar 19, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

After a stent procedure, it is common practice to prescribe anti-platelet medication to prevent the blood from clotting. The main objective of this study is to determine if there is a better medication strategy to prevent blood from clotting and at the same time minimising the number of complications. There are two medication strategies: * Study group: Dual anti-platelet therapy (ticagrelor combined with aspirin) for 1 month, and then ticagrelor alone for another 23 months OR * Control group: Standard treatment, being dual anti-platelet therapy (ticagrelor or clopidogrel combined with aspirin) for 12 months, and then aspirin alone indefinitely

Conditions

  • Coronary Artery Disease (CAD)

Interventions

  • TicagrelorDrug

    Comparison of 1 month of ticagrelor and aspirin followed by 23 months of ticagrelor monotherapy versus 12 months of standard dual anti platelet therapy (DAPT) followed by aspirin monotherapy.

  • Acetylsalicylic AcidDrug

    Comparison of 1 month of ticagrelor and aspirin followed by 23 months of ticagrelor monotherapy versus 12 months of standard dual anti platelet therapy (DAPT) followed by aspirin monotherapy

  • ClopidogrelDrug

    Active Comparator: Reference treatment strategy Acute Coronary Syndrome (ACS) patients incl. unstable angina (UA) patients: ASA and Brilique(ticagrelor) for 12 months followed by 12 months of ASA monotherapy. Stable Coronary Artery Disease (CAD) patients: ASA and clopidogrel for 12 months followed by 12 months of ASA monotherapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With a Composite of All-cause Mortality or Non-fatal New Q-wave Myocardial Infarction (MI)Time frame: 2 year

Locations

130 sites in 18 countries. Site status is shown where the registry gives one.

  • Research centre Brisbane, 6101

    Brisbane, Australia

  • Research centre Melbourne, 6104

    Melbourne, Australia

  • Research centre Melbourne, 6105

    Melbourne, Australia

  • Research centre Graz, 4305

    Graz, Austria

  • Rsearch centre Innsbruck, 4303

    Innsbruck, Austria

  • Research centre Linz, 4304

    Linz, Austria

  • Research centre Vienna, 4301

    Vienna, Austria

  • Research centre Vienna, 4302

    Vienna, Austria

  • Research centre Aalst, 3201

    Aalst, Belgium

  • Research centre Aalst, 3206

    Aalst, Belgium

  • Research centre Bonheiden, 3204

    Bonheiden, Belgium

  • Research centre Charleroi, 3202

    Charleroi, Belgium

  • Research centre Genk, 3205

    Genk, Belgium

  • Research centre Hasselt, 3203

    Hasselt, Belgium

  • Research centre Rio de Janeiro, 5503

    Rio de Janeiro, Brazil

  • Research centre Rio de Janeiro, 5504

    Rio de Janeiro, Brazil

  • Research centre Sao Paulo, 5501

    São Paulo, Brazil

  • Research centre Sao Paulo, 5502

    São Paulo, Brazil

  • Research centre Uberlândia, 5505

    Uberlândia, Brazil

  • Research centre Burgas, 9902

    Burgas, Bulgaria

  • Research centre Plovdiv, 9905

    Plovdiv, Bulgaria

  • Research centre Sofia, 9901

    Sofia, Bulgaria

  • Research centre Sofia, 9903

    Sofia, Bulgaria

  • Research centre Sofia, 9904

    Sofia, Bulgaria

  • Research centre Sofia, 9907

    Sofia, Bulgaria

  • Research centre Sofia, 9908

    Sofia, Bulgaria

  • Research centre Varna, 9906

    Varna, Bulgaria

  • Research centre Newmarket, 1003

    Newmarket, Canada

  • Research centre Quebec, 1001

    Québec, Canada

  • Research centre Copenhagen, 4501

    Copenhagen, Denmark

  • Research centre Roskilde, 4503

    Roskilde, Denmark

  • Research centre Aix en Provence, 3311

    Aix-en-Provence, France

  • Research centre Caen, 3308

    Caen, France

  • Research centre Caen, 3309

    Caen, France

  • Research centre Clermont-Ferrand, 3303

    Clermont-Ferrand, France

  • Research centre Dijon, 3313

    Dijon, France

  • Research centre Grenoble, 3312

    Grenoble, France

  • Research centre Lyon, 3316

    Lyon, France

  • Research centre Nancy, 3314

    Nancy, France

  • Research centre Paris, 3301

    Paris, France

Showing 40 of 130 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.